Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer
Moyer, Jacob A. , Durant, Adri , Nguyen, Mimi V., Mi, Lanyu , Zganjar, Andrew , Shah, Paras , Boorjian, Stephen A. , Tyson, Mark D. , Zganjar, Andrew J., Lyon, Timothy D.

Journal of Urology | June 26, 2025 | Volume: 214 | Issue: 4 | Pages: 393-399

10.1097/ju.0000000000004658 | PMID 40569326 Get It

Stereoelectroencephalography‐guided radiofrequency thermocoagulation for drug‐resistant epilepsy: A meta‐analysis
Pichardo‐Rojas, Pavel S. , Pichardo-Rojas, Diego , Zarate‐Duran, Carlos A., Hjeala‐Varas, Amir, Sanchez‐Velez, Roberto, Barrón‐Lomelí, Aldo , Chavez, Mark, Herrera, Ernesto A. Gutierrez, Torres‐Madrid, Oswaldo, Negida, Ahmed , Milanese, Vanessa, Negida, Ahmed , Chavez, Mario Cesar Torres, Herrera, Ernesto A. Gutierrez, Raslan, Ahmed M

Epilepsia | June 26, 2025 | Volume: 66 | Issue: 10 | Pages: 3602-3620

10.1111/epi.18524 | PMID 40569267 Get It

Abstract Objective In patients with focal drug‐resistant epilepsy (DRE), resective epilepsy surgery correlates with high rates of remission. However, in cases where the epileptic region is deemed surgically inaccessible, or when it involves a complex network, stereoelectroencephalography‐guided radiofrequency thermocoagulation (SEEG‐RFTC) might be an alternative therapeutic strategy. However, most of the available evidence is limited to small observational studies. An updated meta‐analysis is warranted to provide a comprehensive assessment of SEEG‐RFTC in patients with DRE. Methods Databases were searched until September 9, 2023 to identify published studies reporting on the effectiveness of SEEG‐RFTC in patients with DRE. The primary outcomes of interest were the 1‐year seizure‐freedom rate and response rate (50% seizure frequency decrease from baseline). These outcomes were pooled using the inverse variance and a random‐effects model. Results We screened 182 articles and included 16 retrospective cohort studies. A total of 437 unique patients from 12 nonoverlapping cohorts were analyzed for seizure and complication outcomes. The pooled seizure‐free rate after 1 year was 37.8% (95% confidence interval [CI] = 24.7%–50.8%), whereas the seizure response rate after 1 year was 69.7% (95% CI = 52.7%–86.7%). There was high heterogeneity among the included studies. Subgroup analysis revealed that patients with nodular heterotopia achieved higher rates of seizure freedom (57.1%, 95% CI = 38.8%–75.5%) compared to those with cortical dysplasia (CD) and magnetic resonance imaging‐negative conditions. Furthermore, hippocampal sclerosis patients exhibited higher seizure freedom rates (66.7%, 95% CI = 49.8%–83.5%) than those with CD (12.0%, 95% CI = .0%–24.7%). Significance SEEG‐RFTC might be an effective therapeutic option for seizure control in patients with DRE who undergo SEEG for DRE workup. The role of SEEG‐RFTC as a potential adjunct therapy to laser interstitial thermal therapy or surgical resection should be explored. This study highlights the need for well‐designed clinical trials to compare SEEG‐guided RFTC with other therapeutic modalities.
Delirium Severity Trajectories in Critically Ill Adults Using the Intensive Care Delirium Screening Checklist: A Population-Based Cohort
Fiest, Kirsten M. , Lee, Chel Hee , Adefila, Kenny, Lee, Janelle Boram, Khan, Sikandar , Khan, Babar , Krewulak, Karla D. , Krewulak, Karla D , Lindroth, Heidi , Boustani, Malaz

Critical Care Medicine | June 26, 2025 | Volume: 53 | Issue: 9 | Pages: e1748-e1758

10.1097/ccm.0000000000006768 | PMID 40569122 Get It

Objectives: The delirium course of critically ill adults can be classified into trajectories based on the severity and duration of delirium as shown by a recent study. It is unknown whether these trajectories and associated outcomes are reproducible. We aimed to define delirium severity trajectories using the Intensive Care Delirium Screening Checklist (ICDSC) and delirium duration and evaluate the association of trajectory membership with clinical characteristics and 30-day post-discharge mortality. Design: Population-based retrospective cohort. Setting: Fourteen medical-surgical ICUs in Alberta, Canada from January 1, 2014, to December 21, 2019. Patients: We included adult patients (≥ 18 yr old) with an ICU length of stay of greater than or equal to 24 hours, an ICDSC score indicating delirium (≥ 4), and 30-day follow-up data were included. Group-based trajectory modeling identified trajectories over a 7-day period with SAS v9.4 (SAS Institute, Cary, NC). Interventions: None. Measurements and Main Results: Demographic (age, sex) and clinical data (2 × d ICDSC score, comorbidities, illness severity, admission reason, procedures, length of stay, in-hospital, and 30-d post-discharge mortality) were captured from electronic medical records. In total, 21,071 patients were included, with a median age of 59 years (interquartile range, 46–70 yr), 59% male (n = 12,547), and 3% died at 30 days (n = 541). The five-trajectory model was selected. These trajectories followed previously defined patterns: 1) Mild-Brief (19.4%); 2); Severe-Rapid Recovers (18.5%); 3) Severe-Slow Recovers (31%); 4) Mild-Accelerating (14.1%); and 5) Severe-Nonrecovers (16.9%). Trajectory membership was not significantly associated with 30-day post-discharge mortality; however, clinically relevant trends were observed. Conclusions: The current study substantiates the proof-of-concept model of five delirium severity trajectories. Trajectory membership did not predict 30-day post-discharge mortality. Further research is needed to understand the associations between trajectory membership, biological-based biomarkers, and patient-relevant outcomes.
Prognostic Significance of Unintentional Weight Loss in Heart Failure with Preserved Ejection Fraction
Ibe, Tatsuro , Harada, Tomonari , Doi, Shunichi , Tada, Atsushi , Reddy, Yogesh N.V. , Nishimura, Rick , Demmer, Ryan T. , Doi, Shunichi, Naser, Jwan A. , Borlaug, Barry A.

European Journal of Heart Failure | June 26, 2025 | Volume: 27 | Issue: 11 | Pages: 2512-2520

10.1002/ejhf.3745 | PMID 40569185 Get It

Abstract Aims While intentional weight loss achieved through cardiometabolic medications has been associated with robust salutary effects in heart failure (HF) with preserved ejection fraction (HFpEF), the clinical significance of unintentional weight loss in this setting remains unclear. Methods and results This retrospective cohort study included 434 overweight or obese patients with invasively proven HFpEF (67 ± 11 years, 236 female), without weight-reducing therapies or known malignancy, who underwent invasive hemodynamic cardiopulmonary testing and long-term clinical follow-up. The annualized weight change from index to final evaluation for the tertiles was: −21.1 to −1.8 kg/year (tertile 1); −1.8 to 0 kg/year (tertile 2); and 0 to +17.0 kg/year (tertile 3). Patients in tertile 1 had subtle abnormalities in ventilatory control at baseline, but there were no other significant differences between groups across a vast array of haemodynamic and metabolic parameters, both at rest and during exercise. Baseline weight was directly correlated with right and left heart filling pressures (r = 0.23–0.34, p < 0.001), but annualized weight change showed no correlation with any baseline haemodynamic measurements (all p > 0.05). Over a median follow-up of 4.7 years (interquartile range 2.3–6.5), patients in tertile 1 had higher risk of all-cause death (hazard ratio [HR] 3.36, 95% confidence interval [CI] 1.77–6.39, p < 0.001), all-cause death or HF hospitalization (HR 2.49, 95% CI 1.53–4.04, p < 0.001) and cardiac death or HF hospitalization (HR 2.28, 95% CI 1.28–4.07, p = 0.005) compared with those in tertile 2 or 3. These findings were consistent after multivariable adjustment. Conclusions Unintentional weight loss is associated with worse prognosis in patients with HFpEF and overweight or obesity, even as haemodynamics, exercise capacity, and gas exchange are not different from patients with stable or increasing weight. These data underline important and fundamental differences between therapeutic and unintended weight loss in HFpEF.
Biomechanical characteristics of frozen bone allografts after gene therapy-induced revascularization
Rezaie, Elisa S., Visser, Noortje J., Shin, Alexander Y. , Horst, Chantal M.A.M. van der , Ritt, Marco J.P.F. , Bishop, Allen T.

Academia Biology | June 26, 2025 | Volume: 3 | Issue: 2 | Pages: No page available

10.20935/acadbiol7766 | PMID 40837124 Get It

Segmental bone loss reconstruction using frozen bone allografts has a great advantage over amputation. Unfortunately, frozen allografts are avascular, and their use often results in infection, non-union, or fracture. We have attempted to overcome these complications by revascularizing the bone using gene therapy. Segmental tibial bone transplants were performed in 16 Yucatan minipigs. An arteriovenous (AV) bundle was placed intramedullary inside the allografts, which were transfected with growth factors vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) in 8 out of the 16 pigs. Survival time was set at 20 weeks. Bone remodeling and biomechanical properties were tested using histology, compression testing, bone mineralization, and gait analysis. In the growth factor group, five out of eight pigs developed cutaneous vascular tumors, causing excessive bleeding, which led to the exclusion of one pig. Bone remodeling was significantly more present in the VEGF group compared to the control group. This correlated with the amount of pressure the pig allowed on the operated leg for 10 weeks, which was also significantly more (p = 0.029) than the control. Both bone mineralization (p = 0.156) of the area inside the cortex and the amount of stress the allograft could endure before breaking (p = 0.078) seemed to be no different for the VEGF group compared to its healthy contralateral side, which was the control group. We have shown that growth factor-induced frozen allograft bone revascularization using an intramedullary AV bundle results in significantly more bone remodeling and better biomechanical bone properties. However, we encountered benign vascular cutaneous tumors in five out of eight pigs, making the clinical application of this technique impossible at this time.
Neuroimaging Applications of Photon-counting CT
Dogra, Siddhant , Madhavan, Ajay, Madhavan, Ajay A. , Moonis, Gul

Journal of Computer Assisted Tomography | June 26, 2025 | Volume: 50 | Issue: 1 | Pages: 46-53

10.1097/rct.0000000000001776 | PMID 40568956 Get It

Photon-counting computed tomography (PCCT) is a new imaging technology that has advanced diagnostic imaging by offering improved spatial and contrast resolution as well as novel spectral imaging capabilities. Unlike conventional CT, which uses energy-integrating detectors, PCCT employs photon-counting detectors that directly measure individual photon energies, enabling applications such as virtual monochromatic imaging (VMI) and material decomposition. These innovations allow for artifact reduction, better visualization of fine anatomic structures, and improved diagnostic accuracy, all while reducing radiation dose. This review explores select applications of PCCT in neuroimaging, focusing on the brain, temporal bone, and spine. In the brain, we discuss how PCCT demonstrates superior performance for evaluating aneurysms, metallic prostheses, and vessel stenosis, offering enhanced visualization of vascular structures and minimizing artifacts. For temporal bone imaging, we review assessment of both complex anatomy and potentially subtle pathologies such as otosclerosis, as well as visualization of implants like cochlear devices and their intricate components. In spinal imaging, we explore how PCCT improves precise detection of causes of cerebrospinal fluid leaks, improves localization of tiny vessels such as the artery of Adamkiewicz and spinal dural arteriovenous fistulas, and reduces metal artifacts associated with postoperative hardware. PCCT addresses limitations of conventional CT while unlocking new diagnostic possibilities across neuroimaging applications. As clinical adoption of PCCT grows, ongoing research and development will refine imaging protocols and expand its utility. The accumulating evidence underscores PCCT’s transformative potential to improve diagnostic confidence in neuroimaging and beyond.
Hepatobiliary Tumor Board: A Multidisciplinary Review of Challenging Cases
Shah, Amar , Morani, Ajaykumar C. , Tzeng, Ching-Wei D., Das, Koushik K. , Yano, Motoyo , Sonbol, Mohamad Bassam , Shah, Amar S , Tzeng, C.W., Kim, Hyun Woo , Chatterjee, Deyali

Journal of Computer Assisted Tomography | June 26, 2025 | Volume: 49 | Issue: 5 | Pages: 687-697

10.1097/rct.0000000000001733 | PMID 40568981 Get It

Multidisciplinary case conferences have been shown to improve patient outcomes. However, such case conferences may be unavailable in some settings. This multidisciplinary discussion of 4 challenging hepatobiliary cases was presented at the 2023 Society of Advanced Body Imaging Annual Meeting in Dallas, TX. The cases include an “imaging occult” pancreatic tumor, a large pancreatic mass, an intraductal biliary mass, and a polypoid intraluminal gallbladder mass.
Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts
Neidert, Newton B. , Kseibi, Firas, Martin, William P. , Bugazia, Seif, Bendel, Emily C. , Howe, Cassie, Helland, Ryan, Gregory, Adriana , Liestikow, Kathleen, Kline, Timothy L. , Vaughan, Lisa E. , Hogan, Marie C. , Neidert, Newton, Kline, Timothy, Hogan, Marie C , Torres, Vicente E.

Nephrology Dialysis Transplantation | June 26, 2025 | Volume: 40 | Issue: 11 | Pages: 2169-2181

10.1093/ndt/gfaf111 | PMID 40586687 Get It

ABSTRACT Background This medical center migrated from alcohol to sotradecol foam sclerotherapy (SFS) because of perceived improved efficacy in managing symptomatic kidney and liver cysts. We report technical aspects, change in short- and long-term cyst volumes, patient-reported outcomes, safety and applications of the technique. Methods In this retrospective observational study, cases from January 2017 to December 2021 had TKCV/TLCV (per Targeted Kidney or Liver or Cyst analysis) segmented using a deep-learning algorithm and cyst segmentation software (pre-, post-procedure and longitudinally). TKCV/TLCV % change were evaluated using the one-sample Wilcoxon signed rank test. For analyses involving changes in cyst volumes, the median % change in cyst volume per patient was assessed. Longitudinal changes in cyst volumes were assessed using linear mixed models. Changes in quality of life (QOL) [Linear Analog Self-Assessment (LASA), Polycystic Liver Disease Quality of life Questionnaire (PLD-Q) and 12-item short-form (SF12)] were also assessed. Results There were 102 SFS sessions (38 kidney, 58 liver, 6 combined liver/kidney cysts) performed on 77 unique individuals included for analysis. Median [interquartile range (IQR)] % reductions in TKCV were –92.0% (IQR –98.2%, –82.7%, P < .001) and for TLCV were –83.1% (IQR –93.5%, –52.9%, P < .001). Among patients with multiple kidney procedures (n = 7), median % reduction in TKCV was –94.3% (IQR –96.6%, –92.4%, P = .023). For patients with multiple liver procedures (n = 11), median % reduction in TLCV was –63.3% (IQR –85.2%, –28.3%, P = .004). Results were similar among the four patients undergoing multi-stage procedures (n = 1 kidney, n = 3 liver). When measured longitudinally, both liver and kidney cyst volumes declined to levels near 0 mL by 1 year follow-up and remained stable several years later. LASA physical domain and PLD-Q QOL scores improved post-SFS procedure. Conclusion SFS led to substantial long-term reductions in TKCV/TLCV and improved QOL. SFS can augment cyst volume reduction in addition to tolvaptan (kidney cysts) and octreotide (liver cysts). In some individuals with large symptomatic cysts, multiple SFS procedures were safe and effective in reducing TLCV/TKCV and improving symptoms.
Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials
Lamp, Sophia J. , Mazza, Gina L. , Mazza, Gina L

JNCI: Journal of the National Cancer Institute | June 26, 2025 | Volume: 117 | Issue: 9 | Pages: 1938-1941

10.1093/jnci/djaf161 | PMID 40600894 Get It

Abstract More than half of randomized phase 3 oncology trials fail to meet their primary endpoints, often despite favorable results from phase 1 and phase 2 trials. One potential reason for this high failure rate is effect size selection practices for powering these trials. In a systematic review of phase 3 oncology trials published in 10 top medical journals in 2023, we identified a pattern of effect size overestimation for survival endpoints, where the expected hazard ratios (average HR = 0.66) were stronger than those observed in the primary analyses (average HR = 0.72; 2-sided signed-rank test P = .0035). Across 111 trials, 82 of 143 (57.3%) observed hazard ratios for primary survival endpoints were weaker than expected; among 5 journals with 2023 impact factors between 9.9 and 56.7 (vs 58.7-98.4 for the top 5 journals), this ratio was 70.2% (59/84). These results suggest that phase 3 oncology trials are likely underpowered, contributing to the high failure rates in oncology research.
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Kazerooni, Anahita Fathi , Khalili, Nastaran, Liu, Xinyang , Jiang, Zhifan , Pavaine, Julija , Jones, Blaise V. , Sheth, Nakul , McAllister, Aaron S. , Tu, Wenxin , Rodriguez, Andres Fernandez, Shaikh, Ibraheem S , Sanchez-Montano, Mariana , Lai, Hollie Anne , Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammed, Aristizábal, Alejandro , Baid, Ujjwal , Bergquist, Timothy , Conte, Gian-Marco, Eddy, James A. , Ezhov, Ivan , Gandhi, Deep , Gottipati, Anurag , Haldar, Shuvanjan, Janas, Anastasia , Elaine, Elaine, Karargyris, Alexandros , Kassem, Hasan, Khalili, Neda , Maleki, Nazanin , Meier, Zeke, Saluja, Rachit , Sheller, Micah , Shinohara, Russell Takeshi, Viswanathan, Karthik , Wang, Chunhao , Storm, Phillip B. , Packer, Roger, Hummel, Trent R. , Hoffman, Lindsey M. , Nabavizadeh, Ali , Ware, Jeffrey B., Rood, Brian , Resnick, Adam J., Linguraru, Marius George , Khalili, Nastaran, Haldar, Debanjan , Zapaishchykova, Anna , Shah, Lubdha M. , Prabhu, Sanjay P. , Nandolia, Khanak , Anderson, Hannah, Bagheri, Sina , Borja, Austin J. , Calabrese, Evan , Chung, Verena , Familiar, Ariana , Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Moawad, Ahmed W. , Pati, Sarthak , Piraud, Marie , Poussaint, Tina Young , Reitman, Zachary J. , Rudie, Jeffrey D. , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Davatzikos, Christos , Bornhorst, Miriam , Blank, Peter M K de , Aboian, Mariam , Kann, Benjamin H. , Bakas, Spyridon , Vossough, Arastoo

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: June 2025 | Pages: 72-87

10.59275/j.melba.2025-f6fg Get It

Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTS-PEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.